CHAPS is the acronym for the Combined HIV Adolescent Prevention Study.
The standard for HIV prevention care is currently daily Pre-Exposure Prophylaxis (PrEP) using the drug FTC-TDF (formally known as Truvada), which involves taking a tablet every day indefinitely. This can be an effective treatment if used as directed however adherence, toxicity and cost are barriers to it working properly.
Alternative drugs such as FTC-TAF (formally known as TAF) are available as well as less demanding regimes; on-demand PrEP around the time of sexual activity or Post-Exposure Prophylaxis after sex (PEP), but these are less widely researched. We are investigating the protection against HIV that these drugs can offer men when they have sex with women.
Both of the drugs we are investigating are already well-established drugs in the treatment of HIV and FTC-TDF is also used widely as PrEP. We aim to investigate both a daily (PrEP) and on-demand (PEP) prophylaxis for adolescents in sub-Saharan Africa and hope to establish the optimum drug, dose and regime for consistent adherence within this population and therefore protection against HIV.
The CHAPS Study is split into three essential components; the Social Science Study, the Clinical Trial and Laboratory Science Study - Learn more About CHAPS.
This project is part of the EDCTP2
programme supported by the